At a glance
ClinicalIndex Comparison RecordN/ACompleted· 64,684 enrolled
Drug / intervention
Apixaban +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
THE REAL WORLD EVIDENCE ON TREATMENT PATTERNS, EFFECTIVENESS, AND SAFETY OF DRUGS FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS IN KOREA
In Brief
An observational study evaluating Apixaban, Dabigatran, and 3 other interventions for Atrial Fibrillation. Completed, enrolled 64,684 participants across 1 site.
Detailed Summary
The primary purpose of this study is to evaluate comparative effectiveness and safety outcomes of therapies to prevent thromboembolic events in patients with nonvalvular atrial fibrillation by using Korean nationwide health claims database.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
First PostedJun 2018
Primary CompletionDec 2018
TodayJul 2026
First PostedJun 28, 2018
Enrollment StartJan 31, 2018
Primary CompletionDec 20, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.0 years ago
Interventions
Apixabandrug
Treatment for NVAF patients
Dabigatrandrug
Treatment for NVAF patients
Rivaroxabandrug
Treatment for NVAF patients
warfarindrug
Treatment for NVAF patients
Antiplateletsdrug
Treatment for NVAF patients